NASDAQ:OKYO OKYO Pharma (OKYO) Stock Price, News & Analysis $1.07 -0.09 (-7.76%) Closing price 11/20/2026 03:57 PM EasternExtended Trading$1.09 +0.02 (+2.06%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About OKYO Pharma Stock (NASDAQ:OKYO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get OKYO Pharma alerts:Sign Up Key Stats Today's Range$1.04▼$1.2550-Day Range$1.07▼$1.5452-Week Range$1.00▼$3.20Volume76,392 shsAverage Volume304,227 shsMarket Capitalization$56.15 millionP/E RatioN/ADividend YieldN/APrice Target$5.67Consensus RatingModerate Buy Company Overview OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing treatments for inflammatory eye diseases and ocular pain. Its research focuses on therapies intended to reduce inflammation and improve symptoms affecting the eye. The company’s lead candidate, urcosimod (OK-101), is a topical eye-drop treatment being developed for dry eye disease. It is designed to act on ChemR23, a receptor involved in regulating inflammation. OKYO has also investigated the candidate’s potential for treating neuropathic corneal pain.AI Generated. May Contain Errors. Read More OKYO Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreOKYO MarketRank™: 2.571328671325 of 5 starsOKYO Pharma scored higher than 51% of companies evaluated by MarketBeat, and ranked 441st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingOKYO Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialOKYO Pharma has a consensus price target of $5.67, representing about 429.6% upside from its current price of $1.07.Amount of Analyst CoverageOKYO Pharma has only been the subject of 2 research reports in the past 90 days.Read more about OKYO Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for OKYO Pharma are expected to decrease in the coming year, from ($0.13) to ($0.15) per share.Price to Book Value per Share RatioOKYO Pharma has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about OKYO Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.15% of the float of OKYO Pharma has been sold short.Short Interest Ratio / Days to CoverOKYO Pharma has a short interest ratio ("days to cover") of 0.83, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in OKYO Pharma has recently decreased by 40.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOKYO Pharma does not currently pay a dividend.Dividend GrowthOKYO Pharma does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OKYO Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.97% of the stock of OKYO Pharma is held by institutions.Read more about OKYO Pharma's insider trading history. Receive OKYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OKYO Stock News HeadlinesOKYO Pharma to Participate in 2026 Jefferies Global Healthcare Conference in LondonNovember 12, 2026 | globenewswire.comOKYO Pharma to Present at the Stifel 2026 Healthcare ConferenceNovember 5, 2026 | globenewswire.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 21 at 1:00 AM | Base Camp Trading (Ad)Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific MarketsOctober 14, 2026 | markets.businessinsider.comOKYO Pharma Begins Phase 3 Trial Of Urcosimod For Neuropathic Corneal PainOctober 6, 2026 | rttnews.comOKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal PainOctober 6, 2026 | finance.yahoo.comOKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drugOctober 6, 2026 | proactiveinvestors.comOKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal PainOctober 6, 2026 | globenewswire.comSee More Headlines OKYO Stock Analysis - Frequently Asked Questions How have OKYO shares performed this year? OKYO Pharma's stock was trading at $2.07 at the beginning of the year. Since then, OKYO shares have decreased by 48.3% and is now trading at $1.07. When did OKYO Pharma IPO? OKYO Pharma (OKYO) raised $2 million in an IPO on Tuesday, May 17th 2022. The company issued 625,000 shares at $4.00 per share. How do I buy shares of OKYO Pharma? Shares of OKYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OKYO Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that OKYO Pharma investors own include Energy Transfer (ET), Pfizer (PFE), Denison Mine (DNN), Aurora Cannabis (ACB), Atlas Lithium (ATLX), Bitfarms (BITF) and Celsius (CELH). Company Calendar Today11/21/2026Next Earnings (Estimated)12/02/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 4 days ago, OKYO's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:OKYO CIK1849296 Webwww.okyopharma.com Phone44-20-7495-2379FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for OKYO Pharma$5.67 High Price Target$7.00 Low Price Target$5.00 Potential Upside/Downside+429.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.43 Quick Ratio2.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book3.57Miscellaneous Outstanding Shares52,480,000Free Float31,247,000Market Cap$56.15 million OptionableNot Optionable Beta0.02 The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:OKYO) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.